Business
-
Kinaset Therapeutics announced that it has raised $103 million in a Series B financing, with proceeds to be used for development of its KN-002 frevecitinib DPI for the treatment of asthma. The financing was led… Read more . . .
-
Nocion Therapeutics said that it has raised an additional $23 million, expanding a Series B financing that raised $62 million in 2024 for development of the company’s taplucainium DPI for the treatment of chronic cough.… Read more . . .
-
Cipla has launched Afrezza inhaled dry powder insulin for the treatment of diabetes in adult patients in India, the company said. Cipla acquired the rights to market Afrezza in India from MannKind Corporation in 2018,… Read more . . .
-
More than a year after agreeing to merge, DPI developer Pulmatrix, and biopharm Cullgen have agreed to waive a no solicitation clause included in the November 2024 merger agreement. According to the announcement, the companies… Read more . . .
-
Lee’s Pharmaceutical Holdings subsidiary Nova Pneuma has acquired inhaled drug delivery technology and other assets developed by Alexza Pharmaceuticals, the company said. Alexza merged with Grupo Ferrer in 2016. The deal, which is expected to close… Read more . . .
-
US-based start-up CorriXR Therapeutics has announced a partnership with inhaled drug developer InhaTarget Therapeutics and device developer Merxin Ltd for development of an inhaled gene therapy for the treatment of lung cancer. InhaTarget will use its lipid… Read more . . .
-
Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules (glycopyrronium / formoterol / budesonide) and Glenmark Airz FB Smartules (formoterol / budesonide) ampules for the treatment of COPD in India. According to the company, a clinical trial… Read more . . .
-
Chiesi has held an inauguration ceremony for an expanded manufacturing facility in La Chaussée-Saint-Victor, France where the company will manufacture metered dose inhalers with low global warming potential (LGWP) propellants, the company said. Earlier this… Read more . . .
-
Evoke Pharma, which developed and manufactures Gimoti intranasal metoclopramide, has agreed to be acquired by QOL Medical for $11 per share, the companies said. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020. Evoke… Read more . . .
-
Ritedose Corporation announced that it licensed an ANDA for tobramycin inhalation solution from Hikma and that the FDA has approved the company to manufacture and distribute the product. The company noted that tobramycin, which is… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland